Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia

Blood

Volumn 93, Issue 12, 1999, Pages 4149-4153

  O'Brien, Susan ^a   Kantarjian, Hagop ^b   Koller, Charles ^b   Feldman, Eric ^b   Beran, Miloslav ^b   Andreeff, Michael ^b   Giralt, Sergio ^b   Cheson, Bruce ^b   Keating, Michael ^b   Freireich, Emil ^b   Rios, Mary Beth ^b   Talpaz, Moshe ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE; HOMOHARRINGTONINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL PROTOCOL; DOSE RESPONSE; EARLY CANCER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA;

EID: 0033564350     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.12.4149.412k10_4149_4153     Document Type: Article

References (14)

1. th Hospital: Harringtonine in acute leukemia: Clinical analysis of 31 cases. Chin Med J 3:319, 1977
2. th Hospital. Harringtonine in the treatment of acute leukemia: Clinical analyses of 72 cases. Chin Med J 3:163, 1978
3. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP: Phase I clinical investigation of Homoharringtonine. Cancer Treat Rep 68:1085, 1984
4. Neidhart JA, Young DC, Derocher D, Metz EN: Phase I trial of homoharringtonine. Cancer Treat Rep 67:801, 1983
5. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ: Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63:813, 1989
6. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson L, Hester J, Rios M, Andreeff M, Talpaz M: Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86:3322, 1995
7. Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ: Chronic myelogenous leukemia: A multivariate analysis of the associations of patient characteristics and therapy with survival. Blood 66:1326, 1985
8. Kantarjian H, Smith T, O'Brien S, Beran M, Pierce S, Talpaz M, Leukemia Service: Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a therapy. Ann Intern Med 122:254, 1995
9. Mantel N: Evaluation of survival data and two new rank order statistics arising to consideration. Cancer Chemother Rep 50:163, 1966
10. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
11. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441, 1988
12. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820, 1994
13. Montastruc M, Manon FX, Faberes C, Marit G, Bilhou-Nabera C, Cony-Makhoul P, Puntous M, Pigneux A, Boiron JM, Bernard Ph, Salmi R, Broustet A, Reiffers J: Response to recombinant interferon alpha in patients with chronic myelogenous leukemia in a single center: Results and analysis of predictive factors. Leukemia 9:1997, 1995
14. Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizogushi H, Miyawaki S, Tsubaki K, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashima K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K, Kouseisho Leukemia Study Group: A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86:906, 1995